Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus SOX as adjuvant therapy after surgery for gastroesophageal junction cancer
ChiCTR2100046238Phase 4Recruiting
- Sponsor
- The Second Affiliated Hospital of Anhui Medical University
- Start
- May 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in esophagogastric junction cancer and gastric cancer (GC), sponsored by The Second Affiliated Hospital of Anhui Medical University. Primary endpoint: disease free survival. Started May 2021; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
esophagogastric junction cancergastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR2100046238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046238.